Vertex enters new $500M senior unsecured revolving credit facility, replaces 2019 agreement

VERTEX PHARMACEUTICALS INC / MA

$500M revolving facility, matures July 1, 2027; capacity can be increased by an additional $500M.
Interest: base rate +0.000%-0.500% or SOFR +1.000%-1.500%, based on leverage ratio or credit rating.
Financial covenant: consolidated leverage ratio ≤3.50:1 (4.00:1 after material acquisition).
Old 2019 credit agreement terminated and all obligations repaid; related guarantees released.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.